<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210830052344N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-10-02</date_registration>
      <primary_sponsor>Islamic Azad University</primary_sponsor>
      <public_title>Preventive effects of  acupuncture  on nausea and vomiting after cesarean section</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of preventive effect of acupuncture with dexamethasone and ondansetron on nausea and vomiting after cesarean section</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-09-15</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/58425</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: Random allocation in this study is done by simple randomization method. Randomization based on a single sequence of random allocations is called simple randomization. The randomization unit in this study is individual and the random number table tool is used. Random number table is a set of numbers that are generated without a specific pattern or order and in a completely random form and become a table. To use the table of random numbers, we first preset the table to read the numbers (for example, up, down, left Or right) and then we consider numbers for the three groups in question. Consider the numbers  00-29 for intervention A, the numbers 30-59 for intervention B, and the numbers ​​of 60-89 for group C. The researcher then touches one of the numbers and moves in one of the predetermined directions and records the numbers and assigns them to different groups, thus making a random sequence.
Random allocation concealment refers to the method used to execute random sequences on study participants, in a way that prior to individual allocation, group allocated is not specified. In this study, in order to hide the random allocation, the method of opaque envelopes sealed with a random sequence is used. In this method, after making a random sequence based on the sample size of the research, a number of envelopes with aluminum wrapping (in order not to clarify the contents of the envelopes) are prepared and each of the random sequences created is recorded on a card and the card is sealed. Letters are placed in order. In order to preserve the random sequence, the numbering of the envelopes on the outer surface is done in the same way. Finally, the lids of the letter envelopes are glued and placed inside a box, respectively. At the beginning of the registration of participants, based on the order of entry of eligible participants to study, one of the envelopes of the letter is opened in order and the assigned group of the participant is revealed, Blinding description: In this study, participants did not know the type of drug and the time of drug injection and the time of acupuncture.
The intern, as the lead researcher, has no knowledge of the type of drug. Nurses as health personnel do not know the type of medicine.
Data Collectors do not know when the drugs were injected.</study_design>
      <phase>3</phase>
      <hc_freetext>Nausea and Vomiting after cesarean section.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Injectable dexamethasone 8 mg dose is given to the patient about 30 minutes before the operation or immediately after induction of anesthesia. Dexamethasone produced by CHEMIST FACTORY Company. Dexamethasone is a corticosteroid drug and has anti-nausea and anti-emetic properties. Intervention 2: Intervention group 2: Injectable ondansetron 4 mg injection is given intramuscularly or intravenously about 30 minutes before the operation or immediately after induction of anesthesia. (Ondansetron produced by CHEMIST FACTORY Company). It is a serotonergic receptor antagonist and has anti-nausea and vomiting properties. Intervention 3: Control group: Acupuncture: In patients in the control group, we evaluate the effect of acupuncture. Stimulate the PC6 points in both hands after induction of anesthesia with a special needle for one time and for 15 seconds by rotating it clockwise and then remove the needle. The company is the importer of the product (Pars Medical Equipment Company).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is "No more information"</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Milad Johari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 18, The End of 11th Alley, Moallem Ave., Shahrood Town,</address>
        <city>Shahrood</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3613634619</zip>
        <telephone>+98 23 3239 4536</telephone>
        <email>drmiladjohari.med92@yahoo.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Milad Johari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 18, The End of 11th Alley, Moallem Ave., Shahrood Town,</address>
        <city>Shahrood</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3613634619</zip>
        <telephone>+98 23 3239 4536</telephone>
        <email>drmiladjohari.med92@yahoo.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>All class I and II patients of the American Society of Anesthesiologists ( ASA I-II ) who undergo cesarean section surgery under general anesthesia
They receive opioid medications during surgery</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients who have a contraindication to ondansetron or dexamethasone
Patients who have a history of taking drugs that interact with ondansetron or dexamethasone
Patients who have a history of allergies to ondansetron or dexamethasone
Patients who have a mechanical cause for postoperative nausea and vomiting (such as premature obstruction or ileus)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>R10-R19</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Symptoms and signs involving the digestive system and abdomen</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Injectable dexamethasone 8 mg dose is given to the patient about 30 minutes before the operation or immediately after induction of anesthesia. Dexamethasone produced by CHEMIST FACTORY Company. Dexamethasone is a corticosteroid drug and has anti-nausea and anti-emetic properties.</i_keyword>
      <i_keyword>Intervention group 2: Injectable ondansetron 4 mg injection is given intramuscularly or intravenously about 30 minutes before the operation or immediately after induction of anesthesia. (Ondansetron produced by CHEMIST FACTORY Company). It is a serotonergic receptor antagonist and has anti-nausea and vomiting properties.</i_keyword>
      <i_keyword>Control group: Acupuncture: In patients in the control group, we evaluate the effect of acupuncture. Stimulate the PC6 points in both hands after induction of anesthesia with a special needle for one time and for 15 seconds by rotating it clockwise and then remove the needle. The company is the importer of the product (Pars Medical Equipment Company).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Nausea and Vomiting. Timepoint: Nausea and Vomiting before intervention and 2, 24, 48 hours after surgery. Method of measurement: Comparative Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Welfare Fund of Shahrood Azad University Medical School</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-09-05</approval_date>
        <contact_name>Ethics Committee of Islamic Azad University- Shahrood Branch</contact_name>
        <contact_address>No. 17, Adjacent to the Passenger Terminal, Tehran Ave, Shahroud Town, Shahroud Semnan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
